Advertisement|Remove ads.

Dr. Lal Pathlabs Ltd has moved from a long-term downtrend towards a potential uptrend using Wyckoff structure analysis, according to SEBI-registered analyst Harshit Goel.
According to Goel, the stock ended its accumulation stage after May 2022's selling climax, which featured high volume and no downside continuation signaling hidden demand.
Advertisement|Remove ads.
At the time of writing, Dr. Lal Pathlabs shares were trading at ₹2,795.00, down 8.45% year-to-date.
The consistent appearance of higher lows, diminished market volatility, and shrinking supply volumes indicated institutional buying activity.
After surpassing important resistance levels at ₹2,630 and ₹2,757, supported by strong volume, the stock showed a “sign of strength” rally, Goel said.
Advertisement|Remove ads.
He added that the price maintained its position above these levels with reduced selling pressure, which indicates a markup phase starting.
Goel has a positive outlook over the medium term while protecting his position with a stop-loss threshold at ₹2,350.
The stock shows primary support within the range of ₹2,380 to ₹2,757, while the next resistance point stands at ₹2,995, according to the analyst.
Advertisement|Remove ads.
The technical analysis comes after Dr. Lal PathLabs posted strong consolidated results, with net sales increasing to ₹603 crore in the March quarter from ₹545 crore a year ago.
The company's quarterly net profit soared 83.2% to ₹154.80 crore from a year earlier.
Management highlighted volume expansion as its primary strategy by selecting not to increase prices currently.
Advertisement|Remove ads.
The company anticipates FY26 growth between 11% and 12% due to an increase in volume while maintaining steady revenue per patient.
Dr. Lal Pathlabs sees a reduction in margins by 100 basis points to approximately 27% because of investments in geographic expansion and digital initiatives along with talent acquisition and marketing.
The stock has declined 8.5% so far in 2025.
Advertisement|Remove ads.
For updates and corrections, email newsroom[at]stocktwits[dot]com.
Comments posted here will also appear on symbol pages.